Unmasking the U2AF homology motif family: a bona fide protein–protein interaction motif in disguise

SARAH LOERCH¹ and CLARA L. KIELKOPF

Center for RNA Biology and Department for Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA

ABSTRACT

U2AF homology motifs (UHM) that recognize U2AF ligand motifs (ULM) are an emerging family of protein–protein interaction modules. UHM–ULM interactions recur in pre-mRNA splicing factors including U2AF1 and SF3b1, which are frequently mutated in myelodysplastic syndromes. The core topology of the UHM resembles an RNA recognition motif and is often mistakenly classified within this large family. Here, we unmask the charade and review recent discoveries of UHM–ULM modules for protein–protein interactions. Diverse polypeptide extensions and selective phosphorylation of UHM and ULM family members offer new molecular mechanisms for the assembly of specific partners in the early-stage spliceosome.

Keywords: *U2AF1*; *SF3B1*; RRM; UHM; protein–protein interaction

INTRODUCTION

Despite a multitude of interacting subunits, traditional protein–protein interaction motifs are rare among pre-mRNA splicing factors. Approximately 240 proteins are thought to contribute to the pre-mRNA splicing process (Hegele et al. 2012). Nevertheless, the spliceosome contains only five documented WW domains and lacks canonical SH2 or SH3 domains for modular protein–protein interactions. In contrast, more than 200 human proteins are annotated both to contain RNA recognition motifs (RRMs) and to function in pre-mRNA splicing (Swiss-Prot, <http://www.uniprot.org>). An emerging view is that the “super-sized” RRM family can be divided based on divergent sequence elements and functions of the supposed family members (e.g., Blatter et al. 2015, commentary in Loerch and Kielkopf 2015).

The canonical RRM platform centers on two ribonucleoprotein (RNP) consensus motifs and typically binds RNA through key aromatic residues in β -strands. Structures of RRM-containing ribonucleoproteins and seminal spliceosome complexes (Yan et al. 2015; Galej et al. 2016; Rauhut et al. 2016; Wan et al. 2016a,b; Yan et al. 2016) demonstrate that the RRM fold serves as a platform for multiprotein assemblies with RNA. One of the first RRM structures revealed distinct α -helical and β -sheet surfaces of the U2B' RRM bound to the U2A' protein and the U2 small nuclear (sn) RNA (Price et al. 1998). Subsequent structures, including the complex of alternative splicing factors PTB with Raver1

(Rideau et al. 2006; Joshi et al. 2011), intramolecular CPEB1 contacts for polyadenylation (Afroz et al. 2014), and the Snu17p RRM bound to Bud13p in the pre-mRNA retention and splicing complex (RES) (Tripsianes et al. 2014; Yan et al. 2016), establish that separate α -helical and RNP surfaces of the RRM often bind protein and RNA partners simultaneously.

Remarkably, other members of the RRM fold family have adapted for protein–protein interactions in lieu of the ability to bind RNA. In one class of these specialized, protein-binding “RRMs,” the aromatic RNP residues bind protein ligands in lieu of traditional RNA interfaces. The RNP motifs at such protein-interfaces remain similar to those of classical, RNA-binding RRM and as such, can be challenging to distinguish based on primary sequences alone. Examples include Y14–Mago nashi in the exon-junction complex (Fribourg et al. 2003; Lau et al. 2003; Shi and Xu 2003; Bono et al. 2006), the nonsense-mediated decay factors Upf2–Upf3 (Kadlec et al. 2004), and inter-RRM packing of Prp24 in the U2 snRNP (Bae et al. 2007; Montemayor et al. 2014). In other cases, the “RRM” has acquired distinct sequence features for binding proteins, whereas the RNP motifs have diverged and lost the ability to bind RNA. For example, an eIF3j interface with the α -helical region of the eIF3b RRM recruits eIF3b to the 40S ribosome, yet the eIF3b RRM has acidic residues near the RNP motifs and lacks detectable association

¹Present address: Janelia Research Campus, Ashburn, VA 20147, USA

Corresponding author: clara_kielkopf@urmc.rochester.edu

Article and publication date are at <http://www.rnajournal.org/cgi/doi/10.1261/rna.057950.116>.

© 2016 Loerch and Kielkopf This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see <http://rnajournal.cshlp.org/site/misc/terms.xhtml>). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

with RNAs (ElAntak et al. 2007, 2010). Primary sequence features, such as atypical RNP residues or an acidic isoelectric point, often distinguish this latter type of protein-binding “RRM” variants. Among these, the U2AF homology motif (UHM) represents a discrete “RRM-like” family, whose members have lost the ability to bind RNA and instead gained specialized features for recognizing U2AF ligand motifs (ULMs) of protein partners.

Here we focus on recent progress toward understanding and defining the UHM family. Since initial views of UHM–ULM complexes (for review, see Kielkopf et al. 2004), many new UHM–ULM relationships have been revealed, including phosphorylation and polypeptide extensions of core ULM motifs as respective means for UHMs to engage in flirtatious as opposed to stable, monogamous relationships. Recent discoveries of mutant UHM- and ULM-containing splicing factors in myelodysplastic syndromes (MDS) (for review, see Inoue et al. 2016) highlight the importance of understanding how these bona fide protein–protein interaction modules select molecular partners in the assembling spliceosome.

Establishing a “U2AF homology motif” family

The first identified UHM–ULM-mediated complex was that of the eponymous U2 small nuclear ribonucleoprotein (snRNP) auxiliary factor (U2AF) heterodimer (Figs. 1, 2). Initially, the minimal interacting domains of the U2AF heterodimer were mapped to a putative RRM within U2AF³⁵ and a

short region of U2AF⁶⁵ surrounding a singular tryptophan (Zhang et al. 1992; Rudner et al. 1996). The crystal structure revealed an irregular RRM variant of human U2AF³⁵ bound to the tryptophan-containing region of U2AF⁶⁵ (Fig. 2C; Kielkopf et al. 2001), which was recently confirmed for the fission yeast homologs U2AF⁵⁹ and U2AF²³ (Fig. 2D; Yoshida et al. 2015). Shortly thereafter, a C-terminal “RRM” of U2AF⁶⁵ was found to recognize a tryptophan-containing site of SF1 via similar core interactions (Fig. 2A,B; Selenko et al. 2003). Altogether, the U2AF³⁵–UHM–U2AF⁶⁵ ULM and SF1 ULM–U2AF⁶⁵–UHM interactions mediate a SF1–U2AF⁶⁵–U2AF³⁵ ternary complex (Fig. 1), which in turn recognizes consensus pre-mRNA signals at the 3′ splice site via distinct KH and RRM domains. We coined the term “U2AF Homology Motif,” or UHM to distinguish this family from canonical RRM. Although the RRM-like fold is conserved among these U2AF domains, separate sequence motifs have specialized for protein–protein interactions with tryptophan-containing “U2AF Ligand Motifs,” or ULMs (Tables 1–2).

Starting from the U2AF prototypes, sequence similarity searches identified analogous “RRM” variants among diverse proteins (Table 1; Fig. 1; Kielkopf et al. 2004). Many putative UHMs have now been confirmed, either by structure determination or by functional homology (Table 1; Fig. 2E–F). Examples include SPF45 (also called RBM17 and a homolog of DRT111) (Fig. 2E; Corsini et al. 2007), PUF60 (also called FIR) (Corsini et al. 2009), and CAPERα (also called HCC1 or RBM39 and a homolog of PAD-1) (Fig. 2F; Loerch et al. 2014). These three proteins function in alternative splicing (Page-McCaw et al. 1999; Lallena et al. 2002; Dowhan et al. 2005; Hastings et al. 2007; Huang et al. 2012); PUF60 and CAPERα also are coactivators of transcription (Liu et al. 2000, 2001; Jung et al. 2002; Dowhan et al. 2005; Dutta et al. 2008). Other UHM-containing proteins participate in related pathways. A protein kinase, originally called KIS and now UHM kinase 1 (UHMK1), requires an intact UHM for site-specific phosphorylation of SF1 (Manceau et al. 2006, 2008). An inner nuclear membrane protein, MAN1, contains both a UHM and a ULM, and an intramolecular interaction between these motifs is important for downstream functions in the transforming growth factor (TGF)-β signaling pathway (Konde et al. 2010). These additions now establish UHM–ULM interactions as a recurrent protein–protein interaction mode, particularly among early-stage pre-mRNA splicing factors. Nonetheless, the Pfam database (Finn et al. 2016) continues to include UHMs as part of a super-sized RRM family.

FIGURE 1. Multiple UHM–ULM interactions guide the early stages of spliceosome assembly and other pathways. Experimentally confirmed phosphorylation sites of the ULM-containing regions are marked by pink circles. “W” represents ULM tryptophans. Thick gray arrow represents the transition during spliceosome assembly. Thin black arrows represent known UHM–ULM interactions. Arrows toward SF3b155 indicate the general ULM-containing region rather than specific binding sites.

Do UHMs bind RNA?

The UHM shares the core $\beta\alpha\beta\beta\alpha\beta$ topology of an RRM, namely an α/β -sandwich arranged in a four-strand, antiparallel β -sheet packed against two α -helices (Fig. 3). Canonical RRM bind RNA via two conserved RNP motifs in the central β -strands (for review, see Maris et al. 2005): RNP2 in β 1

FIGURE 2. UHM–ULM recognition. (A) Schematic representation of consensus UHM (cyan)–ULM (green) interactions. (B–F) Structures of UHM–ULM complexes, including (B) U2AF⁶⁵ UHM–SF1 ULM (PDB ID: 4FXW); (C) U2AF³⁵ UHM–U2AF⁶⁵ ULM (PDB ID: 1JMT); (D) U2AF²³ UHM–U2AF⁵⁹ ULM (PDB ID: 4YH8); (E) SPF45 UHM–SF3b155 ULM5 (PDB ID 2PEH); and (F) CAPER α UHM–SF3b155 ULM5 (PDB ID: 4OZ1). Magenta spheres mark phosphorylation sites: the SF1 and SF3b155 sites in B,E,F have been confirmed experimentally, whereas the human U2AF⁶⁵ site in C is the predicted phosphorylation of a TP motif. The surface of the central ULM tryptophan is colored yellow, UHM RXF-motifs are blue, and acidic UHM α -helical residues are red; orange spheres are zinc ions on the back surface of the U2AF²³ UHM in D.

(Lahiri and Thomas 1986; Dreyfuss et al. 1988) and RNP1 in β 3 (Fig. 3A; Adam et al. 1986; Sachs et al. 1986). Whereas a subset of RNP residues supports the RRM and UHM folds, the aromatic side chains at the second position of RNP2 and third/fifth positions of RNP1 are required for RRM to bind RNA (e.g., Sickmier et al. 2006; McLaughlin et al. 2011; Bauer et al. 2012). Among confirmed UHMs, the corresponding second/third RNP2/RNP1 residues diverge from the RRM consensus (Table 1; Fig. 3B–E), consistent with dedicated UHM functions for protein–protein rather than protein–RNA interactions. Although early deletion experiments suggested that the U2AF⁶⁵ UHM contributes to RNA binding (Zamore et al. 1992), the flanking RRM was inadvertently truncated. Likewise, our initial report of weak RNA binding by a minimal U2AF³⁵ UHM U2AF⁶⁵ ULM heterodimer (Kielkopf et al. 2001) may have resulted from excess

U2AF⁶⁵ ULM, which weakly binds RNA in the absence of UHM (C Kielkopf, unpubl.). Several groups have now established that stoichiometric complexes of U2AF⁶⁵ UHM–SF1 ULM and U2AF³⁵ UHM–U2AF⁶⁵ ULM (human or fission yeast homologs) lack detectable RNA association in chemical shift and isothermal titration calorimetry (ITC) experiments (Selenko et al. 2003; Soares et al. 2006; Yoshida et al. 2015).

The aromatic residue at the fifth RNP1 position remains conserved among confirmed UHMs (Table 1; Fig. 3)—apart from Tat-SF1, for which only an apo-structure is available (PDB ID: 2DIT). As opposed to RNA contacts, α -helical extensions at the UHM C terminus consistently shield this conserved RNP1 residue from RNA binding (Fig. 3B–D). For the U1A RRM prototype, a similar α -helix occludes the RNP1 in the absence of RNA and rearranges in the RNA-bound conformation (Fig. 3A; Oubridge et al. 1994; Avis et al. 1996). However, this RRM–helix association is likely to be relatively weak; for example, crystallization additives displace the α -helix from the RNP1 surface (Rupert et al. 2003). By comparison, an extensive hydrophobic interface typically packs the amphipathic UHM α -helix against the RNP motifs (Selenko et al. 2003; Corsini et al. 2007, 2009; Loerch et al. 2014). As discussed below, a structure of the U2AF⁶⁵ UHM bound to the N-terminal domain of SF1 further revealed that regions beyond the minimal ULM stabilize this masked UHM conformation (Fig. 3B; Wang et al. 2013; Zhang et al. 2013). It is possible that analogous, ligand-mediated reinforcements of the α -helical block on the UHM “RNA binding surface” will emerge as more UHM-containing structures are determined bound to intact, ULM-containing proteins.

Zinc knuckles mask the U2AF³⁵ and potentially URP ribonucleoprotein motifs

The U2AF³⁵ UHM represents a singular variation of the masked RNP1 (Fig. 3C). Rather than a C-terminal α -helix, the recent structure of the fission yeast homolog, U2AF²³, reveals that N- and C-terminal zinc knuckles (ZnK1 and ZnK2) fold against the “RNP” surface of the UHM (Yoshida et al. 2015). In particular, the C-terminal ZnK2 masks the conserved aromatic residue (Y) at the fifth position of RNP1. Although these conserved ZnK motifs mask the putative RNA binding surface of the U2AF²³, and by analogy, U2AF³⁵ UHMs, the ZnK family typically interacts with RNA (e.g., Hudson et al. 2004; Teplova and Patel 2008). Approximately 10% of MDS-patients harbor acquired mutations of the *U2AF1* gene that encodes the U2AF³⁵ splicing factor (for review, see Inoue et al. 2016). These MDS-relevant *U2AF1* mutations consistently modify the S34 and Q157 residues on the expected RNA binding surfaces of the respective ZnK (Fig. 3C). Indeed, the common S34F mutation alters the RNA binding characteristics of mutant U2AF³⁵-S34F-splicing factor complexes (Okeyo-Owuor et al. 2015; Yoshida et al. 2015). As such, the U2AF³⁵ UHM serves as a scaffold for both the U2AF heterodimer and adjoining ZnK motifs,

TABLE 1. Confirmed and candidate UHM family members

Human UHM protein	Alternate names	RefSeq	Residue range	ULM-partner	RNP2/RNP1	RXF motif	<i>pI</i>	PDB ID(s)
U2AF ⁶⁵	U2AF2	NP_009210	375–475	SF1 SF3b155 Atx1	LCLNMN/CGKIFVEF	RKF	4.5	1OPI, 4FXW, 2M0G
U2AF ³⁵	U2AF1	NP_006749	43–146	U2AF ⁶⁵	IALINI/VGNVYVKF	RWF	4.3	1JMT, 4YH8
URP	ZRSR2	NP_005080	197–303	n.d.	LLIKSM/RGNVYVQY	RWY	4.4	n.d.
SPF45	RBM17	NP_116294	301–401	SF3b155	VLLRNM/AVRIFLEF	RYF	4.8	2PEH
PUF60	FIR, RoBP1, SiaH-BP1	NP_510965	460–559	SF3b155	MVLRNM/IVKIFVEF	RWF	4.3	3DXB (apo)
CAPER α	RBM39, HCC1, RNPC2	NP_004893	411–524	SF3b155	FQLSNM/QGNVYVKC	RWF	5.7	4OZO
Tat-SF1	hTat-SF1	NP_055315	260–353	n.d.	VIKNNM/DGVASVSF	RWF	4.9	2DIT (apo)
KIS	UHMK1	NP_787062	316–415	SF1	VLRLNN/RGQVFVEY	RMF	4.6	n.d.
MAN1	LEMD3	NP_055134	775–880	MAN1	LKIRNM/EGCVYVKC	SWF	8.4	n.d.

Characterized homologs include U2AF⁶⁵, *Saccharomyces cerevisiae* MUD2 or *Schizosaccharomyces pombe* PRP2; Tat-SF1, *Saccharomyces cerevisiae* CUS2 or *Schizosaccharomyces pombe* UAP2; SPF45, *Arabidopsis thaliana* DRT111; CAPER α , *Schizosaccharomyces pombe* Rsd1, *Neurospora crassa* PAD-1. The residue ranges of minimal UHMs were identified by BLAST and structure alignments. The consensus RNP2/RNP1 sequences of RRM s are [ILV]-[FY]-[ILV]-X-N-L/[RK]-G-[FY]-[GA]-[FY]-[ILV]-X-[FY], where X stands for any amino acid and bold residues stack with the RNA bases. The reversed nomenclature of RNP2 before RNP1 primary sequence reflects the history of RRM discovery. The variable “X” position of the RXF motif is underlined. PDB ID codes of the cognate UHM–ULM complexes are given with the exception of PUF60, which is the apo-UHM. (n.d.) Not determined.

which in turn restores RNA binding functions to the U2AF³⁵ UHM.

The most closely related UHM-containing protein to U2AF³⁵ is URP (38% overall sequence identity), which shares a similar domain organization of a central UHM flanked by zinc knuckles (ZnK). Both U2AF³⁵ and URP are the products of frequently mutated genes in MDS patients (*U2AF1* and *ZRSR2*) (for review, see Inoue et al. 2016). However, the U2AF³⁵ mutations alter specific ZnK residues, whereas the URP mutations are randomly distributed throughout the protein sequence and often null. This difference most likely reflects the distinct functions of the two proteins: U2AF³⁵ recognizes the intron-exon junction of the major class of splice sites in conjunction with U2AF⁶⁵ (Merendino et al. 1999; Wu et al. 1999; Zorio and Blumenthal 1999), as opposed to a selective role for URP in a “minor,” stress-associated class of intron splicing (Shen et al. 2010; Madan et al. 2015). Yet, no U2AF⁶⁵ paralog has been identified as a ULM partner for the URP UHM to date.

Shared structural features of UHM–ULM interactions

The core interactions of bona fide UHM–ULM complexes are shared among known structures (Fig. 2A), despite moderate primary sequence conservation (~23% average pairwise sequence identity between matching UHM residues). A critical ULM tryptophan inserts within a hydrophobic pocket between the two α -helices of the UHM “backside” (opposite the RNP β -sheet). A phenylalanine side chain of the UHM caps the base of this pocket and stacks in a “T-type” aromatic interaction (Burley and Petsko 1985) with the tryptophan side chain. This phenylalanine is the third residue of a con-

served “RXF” motif located in a loop connecting the second α -helix and terminal β -strand of the RRM-like fold. The arginine of this loop further encloses the opposite surface of the ULM tryptophan by a salt bridge with the glutamate side chain of the other UHM α -helix. The “X” residue often is an aromatic residue that either faces solvent or interacts with a C-terminal extension of the ULM, as further described below. Preceding the ULM tryptophan, a stretch of basic ULM residues interacts with an acidic UHM α -helix, which also displays a conserved glutamate residue to form the salt bridge abutting the tryptophan. Coupled with the divergence of formerly basic residues for RNA binding by an RRM ancestor, the isoelectric points of UHMs are usually acidic (Table 1). Altogether, the degenerate RNP motifs, RXF motif, acidic α -helix and low isoelectric point, are consensus features that set UHMs apart from canonical, RNA-binding RRM s.

A limited cohort of established “U2AF ligand motifs”

The ULM is highly degenerate and as such, bona fide UHM-partners are challenging to distinguish (Table 2). The consensus elements of the ULM are limited to a central tryptophan and preceding basic residues, which as described above, interact with the respective RXF motif and acidic α -helix of the UHM. A search of the Swiss-Prot database using ScanProsite (de Castro et al. 2006) and the ULM pattern [RK]-X(0,3)-W-[DN]-[EQ] matches more than 9500 protein sequences (out of 551,000 entries), which approaches the expected number of random hits (~14,000) (Nicodeme 2001). Indeed, ULM-like mimics can bind RRM-like domains that lack the consensus UHM features in unexpected

TABLE 2. Confirmed ULM sequences

Human ULM protein	Alternate names	RefSeq	UHM-partner(s)	Minimal ULM sequence	PDB ID
U2AF ⁶⁵ SF1	U2AF2 BBP, ZFM1	NP_009210 NP_004621	U2AF ³⁵ U2AF ⁶⁵	83-EKKKKV RKYWD VPPG-98 14-PSKKRKR SRWNQ DTME-28	1JMT, 4YH8 1OPI, 4FXW, 2M0G
SF3b155	SF3b1	NP_036565	U2AF ⁶⁵ , SPF45, PUF60, CAPER α	191-QPPSKRKR RWD QTADQ-206 (ULM1) 209-GATPKKLSS WDQ AE7P-224 (ULM2) 223-TPGH7PSL RWDE TPGR-238 (ULM3) 245-PGATPGSKI WDP TPSH-260 284-ATSSARKN RWDE TPKT-299 (ULM4) 301-RDTPGHGSG WAE TPRT-316 329-PGASKRKR SRWDE TPAS-344 (ULM5) 756-KILVPSKV WQ GQAFH-771 766-KPAATRKR RW SAPESR-781	2PEH, 4OZO
MAN1 ATX1	LEMD3 Ataxin-1, ATXN1, SCA1	NP_055134 NP_000323	MAN1 U2AF ⁶⁵		n.d. n.d.

Characterized homologs include SF1, *Saccharomyces cerevisiae* MSL5. Minimal 16-residue ULM sequences are shown; additional residues may contribute to UHM interfaces as described in text. Bold residues share similar interactions among known ULM–UHM complexes. Known phosphorylated sites are italicized. The central tryptophan is underlined. The two ULM-like motifs of SF3b155 that lack known UHM-interactions are shaded. (n.d.) Not determined.

ways; for example, a ULM-like region of Bud13p forms an unrelated interface with a Snu17p RRM in the “retention and splicing” (RES) complex (Tripsianes et al. 2014).

Notwithstanding the overwhelming abundance of candidate ULMs, only five ULM-containing proteins have been confirmed to bind UHMs (Table 2). Two well-characterized ULM prototypes include U2AF⁶⁵ and SF1, which respectively partner with the UHMs of U2AF³⁵ and U2AF⁶⁵ for 3' splice site recognition (Figs. 1, 2B–D; Kielkopf et al. 2001; Selenko et al. 2003). Alternatively, the SF1 ULM is recognized by the UHM of the KIS/UHMK1, which directs phosphorylation of an SF1 SPSP motif (Manceau et al. 2006, 2008). Soon thereafter, we and others noticed seven ULM-like repeats in the N-terminal region of the SF3b155 subunit of the U2 snRNP, and confirmed that five of these putative SF3b155 ULMs detectably associate with UHMs (Thickman et al. 2006; Corsini et al. 2007, 2009; Loerch et al. 2014). The SF3b155 ULM–U2AF⁶⁵ UHM complex is likely to assist SF1 displacement and stable association of the U2 snRNP during spliceosome assembly, whereas other UHM-containing splicing factors may regulate this process. Nevertheless, the functional interplays among these multiple SF3b155 ULMs and their UHM partners remain a mystery, as discussed below.

In addition to these early-stage splicing factors, UHMs bind ULM-like sequences of two other nuclear proteins (Fig. 1): the inner nuclear membrane protein MAN1 (also called LEMD3) (Konde et al. 2010) and the neurodegenerative disease-related Ataxin-1 (ATX1) (de Chiara et al. 2009). An intramolecular ULM–UHM interaction within MAN1 is thought to regulate its association with SMAD2 (Konde et al. 2010), which in turn represses TGF- β signaling for bone development (Hellemans et al. 2004; Lin et al. 2005;

Pan et al. 2005). A ULM sequence near the C terminus of ATX1 binds the UHMs of U2AF⁶⁵ (Lim et al. 2006; de Chiara et al. 2009) or SPF45 (Lim et al. 2008; de Chiara et al. 2009). Further, U2AF⁶⁵ colocalizes in large inclusions of polyglutamine-expanded ATX1, which are characteristic of triplet-repeat expansion in spinocerebellar ataxia type 1 (de Chiara et al. 2009). As such, sequestration of UHM-containing proteins by ATX1 aggregates may contribute to the pathogenesis of this disease.

Potential functions of multiple functions of multiple SF3b155 ULMs

The presence of five confirmed ULMs in human SF3b155, rather than an isolated ULM, is unusual among ULM-containing proteins. Notably, the SF3b155 subunit is produced by the *SF3B1* gene, which frequently harbors mutations of a distinct, HEAT repeat domain in MDS patients (for review, see Inoue et al. 2016). Considering that recurrent splicing factor mutations in MDS are heterozygous, rarely null, and typically affect specific accessory interactions, even the absence of MDS-relevant mutations among SF3b155 ULMs suggests essential functions for this protein region. The SF3b155 ULMs are embedded within an intrinsically disordered region (IDR) of this protein, as reflected by low sequence complexity and the absence of well-defined structure in the absence of bound UHM (Thickman et al. 2006). As such, the SF3b155 ULMs are likely to share the typical function of IDRs as dynamic signaling hubs for protein-interaction networks (for review, see Wright and Dyson 2015). The structures of individual SF3b155 ULMs bound to UHMs, including those of SPF45 and CAPER α (Fig. 2E,F;

FIGURE 3. RNP interactions. (A) N-terminal RRM of U1A prototype bound to RNA ligand. The RNP surfaces of UHM (cyan)–ULM (green) complexes, including (B) U2AF⁶⁵ UHM–SF1 ULM (PDB ID: 4FXW); (C) U2AF²³ UHM–U2AF⁵⁹ ULM (PDB ID: 4YH8); (D) SPF45 UHM–SF3b155 ULM5 (PDB ID 2PEH); and (E) CAPER α UHM–SF3b155 ULM5 (PDB ID: 4OZ1). The conserved aromatic residue at RNP1 position 5 typically is masked by a C-terminal extension (magenta) of the core UHM fold. The key residues at positions 2 of RNP2 and positions 3/5 of RNP1 are colored blue. Orange spheres represent zinc ions. Indigo, space-filling residues in C correspond to MDS-relevant mutations of the human homolog. Views are following an $\sim 120^\circ$ rotation about the y-axis relative to Figure 2.

Corsini et al. 2007; Loerch et al. 2014), show the typical core UHM–ULM interactions described above. Yet, several lines of evidence indicate that these structures may be only headlines of an epic story.

The question of how many of SF3b155 ULMs can be occupied concurrently has been addressed separately for the UHMs of U2AF⁶⁵ and CAPER α . The apparent stoichiometry of ITC experiments suggests that up to three U2AF⁶⁵ UHMs can associate with the ULM-containing region of SF3b155 (Thickman et al. 2006). Consistent with findings for the U2AF⁶⁵ UHM, a battery of methods including size exclusion chromatography, amino acid analysis, and ITC show that two CAPER α UHMs concurrently bind the SF3b155 ULM-containing region under saturating conditions (Loerch et al.

2014). The Hill coefficient of pull-downs from human cell extract further suggests that endogenous, full length CAPER α binds a GST-fused ULM-containing region of SF3b155 with positive cooperativity (Loerch et al. 2014). Despite the ability of multiple UHMs to concurrently bind the ULM-containing region of SF3b155, a one-to-one complex with U2AF⁶⁵ is thought to recruit the SF3b155-tethered U2 snRNP to the pre-mRNA splice site during the early stages of spliceosome assembly (Gozani et al. 1998). Instead, other UHM-containing alternative splicing factors, such as CAPER α , may co-assemble with the U2AF⁶⁵–SF3b155 complex.

Whether each of the multiple SF3b155 ULMs has “promiscuous” or “monogamous” relationships with UHM-containing protein partners also remains in question. Although a large number of UHM–ULM binding experiments are now complete (Table 3), the binding affinities for distinct ULM-like SF3b155 sites have rarely been comprehensively quantified for a given UHM-containing protein. To date, available evidence suggests that the constitutive splicing factor U2AF⁶⁵ prefers to bind a distinct SF3b155 ULM (ULM5) (Table 2; Thickman et al. 2006) rather than compete with alternative splicing factors, although excess U2AF⁶⁵ can associate with more than one ULM in vitro. Pull-down assays of full-length CAPER α by a series of SF3b155 IDR variants, each containing a single unmodified ULM, followed by ITC experiments using the three ULM peptides that detectably bound, show that CAPER α UHM has highest affinity for the first SF3b155 ULM (ULM1) (Loerch et al. 2014). Likewise, ITC and NMR data implicated SF3b155 ULM1 as the preferred binding site of the PUF60 UHM, compared to ULM2 or ULM5 (Corsini et al. 2009). These five- to sevenfold preferences of the CAPER α and PUF60 UHMs for binding the ULM1- over ULM5-containing SF3b155 variants or fragments, compared to the converse preference of the U2AF⁶⁵ UHM for the distally located ULM5, suggests that the CAPER α or PUF60 splicing factors can concurrently bind SF3b155 alongside U2AF⁶⁵. Accordingly, U2AF⁶⁵ and PUF60 have synergistic effects on splicing in vitro (Hastings et al. 2007).

IDRs such as the SF3b155 ULM-containing region often coordinate the synergistic action of multiple weak binding sites to modulate positive or negative allostery, as recently exemplified for coordination of host CBP or pRB proteins by the adenoviral protein E1A (Ferreon et al. 2013). The ULM-containing region of SF3b155 adjoins its binding site for p14, an RRM-like U2 snRNP subunit that ultimately contacts the branch point sequence of the pre-mRNA (Will et al. 2001; Cass and Berglund 2006; Schellenberg et al. 2006; Spadaccini et al. 2006). Considering the above data, multiple UHM-containing proteins are likely to simultaneously associate with the SF3b155 IDR alongside the p14 subunit, possibly with positive cooperativity (Fig. 1). A potentially analogous precedent for cooperative assembly of an RRM-mediated spliceosome subcomplex has been set by the RES hetero-trimer of the RRM-like Snu17p, ULM-like Bud13p, and Pml1p (Tripsianes et al. 2014; Wysoczanski et al. 2014).

Emerging roles of ULM extensions for UHM specificity

The core interactions of UHM–ULM complexes are conserved, namely the electrostatic interactions between the acidic UHM α -helix and the basic ULM tail as well as the UHM RXF-mediated pocket for the ULM-tryptophan. This raises the question of how different UHMs distinguish the locally similar, yet functionally diverse, ULMs of SF1, U2AF⁶⁵, SF3b155, MAN1, or ATX1 partners from numerous ULM-like sequences in the proteome. Indeed, UHM-containing proteins exhibit binding preferences for distinct ULM-containing proteins (Table 3). The U2AF³⁵ UHM–U2AF⁶⁵ ULM complex is more than 1000-fold preferred over off-target U2AF³⁵ UHM–SF1 ULM or CAPER α –U2AF⁶⁵ ULM interactions (Corsini et al. 2007; Stepanyuk et al. 2016). Likewise, the U2AF⁶⁵ UHM–SF1 ULM complex is at least 200-fold preferred over an erroneous U2AF⁶⁵ UHM–U2AF⁶⁵ ULM homodimer (Corsini et al. 2007). Other U2AF⁶⁵ UHM–ULM complexes that serve alternative functions more closely approach the affinity of its SF1 complex. For example, the U2AF⁶⁵ UHM prefers binding the SF1 ULM over SF3b155 ULM5 peptides by 18-fold (Thickman et al. 2006); the U2AF⁶⁵–SF3b155 complex may either be strengthened in the context of full length proteins or assist U2AF displacement during the sequential stages of pre-mRNA splicing. The affinity of the U2AF⁶⁵ UHM for unphosphorylated ATX1 ULM approaches its affinity for SF1, but decreases following ATX1 phosphorylation; accordingly, ATX1-phosphorylation is thought to regulate competitive binding to U2AF⁶⁵ versus a 14-3-3 protein signaling scaffold (de Chiara et al. 2009). The splicing and transcription regulator CAPER α strongly prefers to bind the intact SF3b155 ULM-containing region (e.g., by nearly 200-fold compared with SF1) (Loerch et al. 2014). The SPF45 and PUF60 UHMs also show subtle preferences for binding a representative SF3b155 ULM peptide (ULM5) over SF1 or U2AF⁶⁵ ULMs, which may be enhanced in the context of the intact SF3b155 domain, as observed for CAPER α . These CAPER α , SPF45 and PUF60 associations with SF3b155 may regulate the second, U2 snRNP-dependent step of splicing, which has been shown for SPF45 (Lallena et al. 2002). Although the structural basis of SF3b155 ULM–UHM specificity remains limited to core interactions, structures of U2AF⁶⁵ UHM and U2AF³⁵ UHM complexes bound to larger SF1 or U2AF³⁵ fragments reveal unexpected roles for ULM extensions in conferring the UHM–ULM specificity of these two complexes.

An early clue to the underpinnings of UHM–ULM specificity was obtained from the crystal structure of the human U2AF³⁵ UHM–U2AF⁶⁵ ULM complex (Kielkopf et al. 2001). At the C terminus of the U2AF⁶⁵ ULM, a short proline/aromatic-rich sequence encloses an exposed U2AF³⁵ UHM tryptophan at the X-position of the RXF motif (Fig. 2C) and is required for high affinity interactions. This hydrophobic ULM sandwich is conserved for the fission yeast

U2AF heterodimer (Fig. 2D) and encloses the UHM RWF-motif in an analogous manner as the human homolog. The “X” residues of several other UHM RXF motifs also are aromatic, including tryptophan residues for the PUF60, Tat-SF1, and MAN1 UHMs. Accordingly, a TP motif in the C-terminal region of the SF3b155 ULM is similarly positioned adjacent aromatic side chains in the RXF motifs of the CAPER α and SPF45 UHMs (Corsini et al. 2007; Loerch et al. 2014). In contrast, structurally distinct lysine and methionine residues mark the RXF motifs of the U2AF⁶⁵ and KIS UHMs, which may be related to the preference of these UHMs to target SF1 over SF3b155. Although C-terminal extensions of an SF3b155 ULM5 peptide only subtly increase its binding affinity for the CAPER α UHM (Loerch et al. 2014), it is conceivable that analogous interactions between the proline-rich inter-ULM linkers of SF3b155 and aromatic residues in UHM RXF motifs contribute to UHM specificity in the context of the intact SF3b155 ULM-containing region.

The role of C-terminal ULM extensions in cognate UHM specificity is dramatically illustrated by a striking coiled-coil extension of the SF1 ULM (Figs. 1B, 2B; Wang et al. 2013; Zhang et al. 2013). The N-terminal α -helix of the SF1 coiled-coil mediates the primary contacts between this domain and the U2AF⁶⁵ UHM (Fig. 1B). Following a disordered linker to the ULM, the N-terminal section of this SF1 α -helix packs against both the U2AF⁶⁵ RNP2 and a C-terminal α -helical tail of the UHM, which in turn masks the RNP1 (Fig. 2B). Thereby, the SF1 coiled-coil converts the putative RNA binding surface of the RRM-like fold into a protein–protein interface. Although a similar α -helix extends the RRM-like fold of most UHMs (Fig. 2D–E), a unique tryptophan residue of U2AF⁶⁵ mediates a cation– π interaction with an arginine residue in the SF1 coiled-coil. A lysine in the U2AF⁶⁵ RXF loop, which differs from the typical aromatic X-residues of other UHMs, further recognizes the C-terminal region of the same SF1 α -helix via a specific salt bridge. The SF1 coiled-coil confers only a few fold higher affinity for the U2AF⁶⁵ UHM compared to the minimal ULM, likely due to an entropic cost of local folding-on-binding. Nevertheless, the specific interactions among the C-terminal U2AF⁶⁵ tryptophan, lysine in the RXF loop, and the SF1 coiled-coil residues, are likely to specify this cognate UHM–ULM complex.

Remarkably, the N terminus of the fission yeast U2AF⁵⁹ ULM is extended at by a distinct, anti-parallel coiled-coil with the C-terminal, α -helical extension of the U2AF²³ UHM and second ZnK (Fig. 1D). The appended U2AF⁵⁹ and U2AF²³ α -helices, which were absent from the original U2AF⁶⁵–U2AF³⁵ structure (Kielkopf et al. 2001), are weakly conserved in the human primary sequences and instead appear to have been partly replaced by arginine-rich residues. With the exception of crystal contacts by SPF45-bound SF3b155 (Corsini et al. 2007), the N-terminal ULM residues are disordered in all UHM–ULM structures other than the

TABLE 3. Apparent equilibrium dissociation constants (K_D) of ULM–ULM complexes determined by ITC

UHM	ULM	ULM residue range	K_D (nM)	Condition	Reference
U2AF⁶⁵ (UHM)	SF1 (ULM)	13–28	23.8 ± 3.8	A	(Thickman et al. 2006)
(UHM)	(ULM + CC + RBD)	1–255	1.8 ± 3.8	A	(Thickman et al. 2006)
(UHM)	(ULM)	1–25	1600 ± 40	B	(Corsini et al. 2007)
(UHM)	(ULM)	1–25	127 ± 48	C	(Zhang et al. 2013)
(UHM)	(ULM + CC)	1–145	84 ± 23	C	(Zhang et al. 2013)
(RBD + UHM)	(ULM + CC + RBD)	1–260	114 ± 23	C	(Zhang et al. 2013)
(RBD + UHM)	Phospho-SF1 (ULM + CC + RBD)	1–260	96 ± 32	C	(Zhang et al. 2013)
(UHM)	U2AF⁶⁵ (ULM)	85–112	$>300,000$	B	(Corsini et al. 2007)
(UHM)	SF3b155 (ULMs 1–5)	190–344	2833 ± 23	A	(Thickman et al. 2006)
(UHM)	(ULM5)	329–344	449 ± 75	A	(Thickman et al. 2006)
(UHM)	(ULM5)	317–357	6700 ± 200	B	(Corsini et al. 2007)
(UHM)	Atx1 (ULM)	769–777	5600 ± 300	B	(de Chiara et al. 2009)
(UHM)	(ULM)	769–779	$18,400 \pm 700$	B	(de Chiara et al. 2009)
(UHM)	Phospho-Atx1 (ULM)	769–777	9200 ± 300	B	(de Chiara et al. 2009)
(UHM)	(ULM)	769–779	$35,800 \pm 1300$	B	(de Chiara et al. 2009)
U2AF³⁵ (UHM)	U2AF⁶⁵ (ULM)	85–112	1.7 ± 0.8	A	(Kielkopf et al. 2001)
(UHM)	(ULM)	85–112	135 ± 9	B	(Corsini et al. 2007)
(UHM)	SF1 (ULM)	1–25	$>150,000$	B	(Corsini et al. 2007)
(UHM)	SF3b155 (ULM5)	317–357	$>150,000$	B	(Corsini et al. 2007)
SPF45 (UHM)	SF3b155 (ULM5)	317–357	1100 ± 10	B	(Corsini et al. 2007)
	SF1 (ULM)	1–25	2600 ± 100	B	(Corsini et al. 2007)
	U2AF⁶⁵ (ULM)	85–112	3900 ± 200	B	(Corsini et al. 2007)
	Atx1 (ULM)	769–779	$23,400 \pm 1500$	B	(de Chiara et al. 2009)
	Phospho-Atx1 (ULM)	769–779	$40,000 \pm 1600$	B	(de Chiara et al. 2009)
PUF60 (UHM)	SF3b155 (ULMs 1–2)	194–229	1000 ± 200	B	(Corsini et al. 2009)
	(ULM5)	317–357	5600 ± 600	B	(Corsini et al. 2009)
	U2AF⁶⁵ (ULM)	85–112	1600 ± 40	B	(Corsini et al. 2009)
	SF1 (ULM)	1–25	$20,800 \pm 5200$	B	(Corsini et al. 2009)
CAPERα (UHM)	SF3b155 (ULMs 1–5, Site 1)	190–344	58 ± 2	A	(Loerch et al. 2014)
	(ULMs 1–5, Site 2)	190–344	330 ± 4	A	(Loerch et al. 2014)
	(ULM1) ^a	190–344	2300 ± 100	A	(Loerch et al. 2014)
	(ULM4) ^a	190–344	$68,000 \pm 1900$	A	(Loerch et al. 2014)
	(ULM5) ^a	190–344	$14,000 \pm 1800$	A	(Loerch et al. 2014)
	(ULM5)	333–342	2400 ± 10	A	(Loerch et al. 2014)
	(ULM5)	333–355	2300 ± 200	A	(Loerch et al. 2014)
	U2AF⁶⁵ (ULM)	85–112	6500 ± 1100	A	(Loerch et al. 2014)
	(ULM)	85–112	$20,500 \pm 2800$	D	(Stepanyuk et al. 2016)
	SF1 (ULM + CC)	14–132	$11,000 \pm 700$	A	(Loerch et al. 2014)

Condition A: 25 mM HEPES pH 7.4, 50 mM NaCl, 30°C.

Condition B: 50 mM sodium phosphate buffer pH 7.0, 150 mM NaCl, 22°C.

Condition C: 20 mM sodium phosphate buffer pH 7.0, 50 mM NaCl, 25°C.

Condition D: 20 mM Tris–HCl pH 7.0, 100 mM NaCl, 25°C.

Proteins are shown in boldface.

(CC) Coiled-coil; (RBD) RNA binding domain.

^aULM-containing region of SF3b155 with alanine mutations of all ULM tryptophans except named ULM.

U2AF⁵⁹–U2AF²³ heterodimer. Together with the observation that multiple mutations of these typically basic residues are needed to abolish detectable SF1–U2AF⁶⁵ interactions (Selenko et al. 2003), this N-terminal ULM region is likely to contribute avidity, whereas the ordered U2AF⁵⁹ α -helix confers specificity for the U2AF²³ heterodimer. Given these new precedents for extended U2AF⁶⁵–SF1 and U2AF⁵⁹–U2AF²³ heterodimers, it now remains to be seen whether regions adjoining the SF3b155, MAN1, and ATX1 ULMs likewise guide specific complexes with UHM-containing proteins.

ULM phosphorylation regulates partnerships with UHMs

Dynamic phosphorylation and dephosphorylation of splicing factors regulate spliceosome assembly and selection of splice sites (for review, see Naro and Sette 2013). For example, region-specific phosphorylation of serine–arginine rich proteins is well-known to regulate splicing factor localization and spliceosome assembly (for review, see Zhou and Fu 2013). For several ULM-containing proteins, including SF1, ATX1, and potentially U2AF⁶⁵ and SF3b155,

phosphorylation has emerged as a means for regulating their UHM partnerships and downstream functions.

The first example of phosphorylation regulating ULM–UHM interactions was noted for a serine in the SF1 ULM (S20, Fig. 2B; Wang et al. 1999). Phosphorylation of this site by cGMP-dependent protein kinase-I reduces SF1 association with U2AF⁶⁵ and thereby inhibits spliceosome assembly. Structurally, the phosphorylated SF1 S20 would disrupt a hydrogen bond and electrostatically repel a conserved aspartate residue (D401) in the acidic α -helix of the U2AF⁶⁵ UHM (Wang et al. 2013). Two of the SF3b155 ULMs display serine residues at analogous positions as SF1 S20, including SF3b155 S216 and S336 in ULM2 and ULM5; phosphorylation of SF3b155 S216 has been confirmed in an acute myeloid leukemia cell line by mass spectrometry (Weber et al. 2012). The similar positions of serines among these ULMs suggest that phosphorylation could coordinately dissociate U2AF⁶⁵, and possibly other SF3b155-associated UHM-containing proteins, from SF3b155 and SF1.

A loop between the two α -helices of the SF1 coiled-coil domain harbors a highly conserved “SPSP” sequence motif (Fig. 2B), which is primarily in the phosphorylated state for SF1 isolated from human embryonic kidney cells (Manceau et al. 2006). This SPSP-phosphorylation event subtly increases the binding affinity of SF1 for U2AF⁶⁵ (Manceau et al. 2006; Zhang et al. 2013), most likely by stabilizing the coiled-coil fold of the phosphorylated SF1 domain. Structures of the SPSP-phosphorylated SF1 bound to the U2AF⁶⁵ UHM shows that the phosphorylated serines coordinate three arginine residues and induce folding of an otherwise disordered linker between the two α -helices of the coiled-coil (Wang et al. 2013; Zhang et al. 2013). The UHM-containing KIS kinase specifically phosphorylates the SPSP motif of SF1 (Manceau et al. 2006), and KIS-knockout mice showed subtle changes in gene expression and specific behaviors, including spontaneous activity and contextual fear conditioning (Manceau et al. 2012). However, 2D electrophoresis showed that the majority of endogenous SF1 remains in the SPSP-phosphorylated form following KIS-knockout. This result implicates other kinases in regulating the SF1 SPSP site, and leaves the potentially pluripotent functions of SF1 SPSP-phosphorylation an open question.

The most recent member of the ULM-containing family, ATX1, is a phosphorylation-sensitive molecular switch that discriminates between two ligands, U2AF⁶⁵ and the multifunctional regulatory protein 14-3-3 (de Chiara et al. 2009). An S776 residue immediately adjacent the ULM tryptophan of ATX1 is phosphorylated by Akt kinase (Chen et al. 2003). The 14-3-3 protein was shown to effectively outcompete the U2AF⁶⁵ UHM for binding at the phosphorylated ATX1 site, which overlaps the ATX1 ULM. Initial investigations with phospho-mimetic S776D mutations of ATX1 in mouse models suggested that phosphorylation of S776 also recruits SPF45 to ATX1 complexes (Lim et al. 2008). Although the apparent enhancement of ATX1–SPF45 associ-

ation by S776 phosphorylation could not be recapitulated by ULM-containing peptides binding the isolated UHM in vitro (de Chiara et al. 2009), it remains possible that the phosphorylation-sensitivity depends on the context of the intact proteins. Notably, the abnormal expansion of an ATX1 polyglutamine-repeat in the neurodegenerative disease spinocerebellar ataxia type 1 requires the S776 residue of ATX1 and enhances ATX1–SPF45 association in vivo (Lim et al. 2008), which sets a precedent for the contribution of ULM phosphorylation to pathogenicity.

These well-characterized examples of phosphorylation-sensitive UHM–ULM interactions are only the tip of the iceberg. Numerous ULM-associated phosphorylation sites remain to be investigated. In a striking example, abundant phosphorylated threonine–proline (TP) motifs riddle the N-terminal IDR of SF3b155, including 29 TP sequences of which 18 are experimentally verified, phosphorylation sites in the Phospho.ELM database (Dinkel et al. 2011). The U2AF⁶⁵ and MAN1 ULMs also contain single TP motifs, whereas the SF1 and ATX1 ULMs have none. In known structures, including the U2AF⁶⁵ ULM–U2AF³⁵ UHM heterodimer and SF3b155-ULM complexes with SPF45 or CAPER α UHMs, a TP motif located a few residues C terminal to the central ULM tryptophan packs near an exposed aromatic residue at the X-position of the UHM RXF-motif (Fig. 2B–F). Although the structural effects of ULM TP phosphorylation are currently unknown, one can envision that the proximity of the phosphorylated TP to the UHM RXF motif could result in steric clashes, anion– π repulsion, or conformational changes following peptidyl–prolyl-isomerization, which are well-known to switch *cis/trans* propensity following TP phosphorylation (for review, see Wulf et al. 2005).

Whether phosphorylation of these ULM-associated TP motifs controls selective ULM–UHM associations, or acts as a general “off” switch, remains a topic for speculation. While it has been shown that SF3b155 is successively phosphorylated and dephosphorylated during spliceosome assembly (Wang et al. 1998; Boudrez et al. 2002; Shi et al. 2006), a direct link to the ULM-proximal TP motifs has yet to be established. The SF3b155 subunit is phosphorylated in vitro by cyclin B–cdk1 and cyclin E–cdk2 (Seghezzi et al. 1998; Boudrez et al. 2002), which also co-immunoprecipitate with SF3b155 from cell lysates, and SF3b155 phosphorylation significantly increases during mitosis (Seghezzi et al. 1998). However, various TP motifs in the SF3b155 IDR are predicted by NetPhosK (Blom et al. 2004) to be phosphorylated by at least ten different kinases. Altogether, these observations point to selective, as well as coordinated, regulation of ULM-associated TP motifs by phosphorylation.

Summary and perspectives

Significant progress toward establishing a network of UHM–ULM interactions (Fig. 1) has been made since the discovery of these RRM-like protein–protein interaction domains

fifteen years ago. Most suspected members of the UHM family have now been structurally confirmed and implicated in UHM–ULM partnerships. Since the first U2AF⁶⁵ ULM–U2AF³⁵ UHM and SF1 ULM–U2AF⁶⁵ UHM prototypes (Kielkopf et al. 2001; Selenko et al. 2003), structures of SPF45 and CAPERα UHMs reveal similar core interactions with the individual SF3b155 ULMs (Corsini et al. 2007; Loerch et al. 2014). The apo-PUF60 UHM structure also has been determined and the PUF60 UHM binds an SF3b155 ULM (Corsini et al. 2009). The UHM-containing KIS kinase has been shown to selectively phosphorylate SF1 in a ULM-dependent manner (Manceau et al. 2006). These UHM–ULM partnerships are likely to contribute to spliceosome assembly and alternative splicing, yet new functional roles for UHM–ULM protein interaction modules continue to emerge. An intramolecular UHM–ULM switch in the inner nuclear membrane protein MAN1 regulates SMAD2 binding for TGF-β signaling (Konde et al. 2010). Similarly, a ULM in the glutamine-repeat expanded ataxin protein competes for UHM-mediated association with U2AF⁶⁵ versus a phosphorylation-sensitive, 14-3-3 protein signaling hub (de Chiara et al. 2009). Altogether, these recent findings demarcate a bona fide UHM family of ULM-interaction modules (Fig. 3), underlying a deceptively RRM-like charade.

An outstanding question is whether new members of the UHM family will be discovered in the future. To date, nine UHM family members (consolidating U2AF⁶⁵/MUD2, SPF45/DRT111, Tat-SF1/CUS2/UAP2, CAPERα/PAD-1/Rds1 homologs) were first identified based on primary sequence searches (Kielkopf et al. 2004) and now have been shown to partner with ULM-containing proteins (Table 1). Seven atypical RRMs with sequence features that appeared distantly related to UHMs also were flagged previously (Kielkopf et al. 2004). Among these candidates, new structures already rule out UHM-type interactions for the N-terminal RRMs of Prp24 and SAP49. Even so, these Prp24 and SAP49 RRMs do function in protein–protein interactions. The N-terminal RRM of Prp24 utilizes the RNP1/RNP2 surface to bind a neighboring RRM rather than RNA (Bae et al. 2007; Montemayor et al. 2014). The N-terminal SAP49 RRM engages a neighboring Cus1 subunit in the activated yeast spliceosome (Yan et al. 2016) via a tryptophan-mediated interaction that is qualitatively similar to a UHM. In addition to the SAP49–Cus1 complex (Yan et al. 2016), new examples of tryptophan-mediated interactions with RRM-like domains have emerged outside the UHM family, including eIF3b–eIF3j in the translation initiation complex (ElAntak et al. 2010), Snu17p–Bud13p in the RES complex (Tripsianes et al. 2014), mRNA export complexes of viral proteins with AlyREF (Tunncliffe et al. 2011; Tunncliffe et al. 2014), and an intramolecular interface of CPEB1 (Afroz et al. 2014). The exact conformations of the tryptophan-containing ligands differ among these atypical RRMs, which also lack the RXF motif, acidic α1, and C-terminal α-helix of UHMs. Also unlike UHMs, SAP49, Snu17p and CPEB1 simultane-

ously bind RNA and protein partners. As such, tryptophan-mediated protein–interactions with atypical, RRM-like domains represent a recurring theme among ribonucleoprotein complexes that is likely to expand in the future.

Hitherto, a skeleton in the UHM family closet has been the remarkably similar core interactions with ULMs, which raise the conundrum of how specific UHM–ULM partnerships are arranged. Several answers to this puzzle have begun to fall into place. New structures of larger U2AF and SF1 complexes implicate regions adjoining the ULMs as accessories for UHM engagement (Wang et al. 2013; Zhang et al. 2013; Yoshida et al. 2015). Phosphorylation sites within and flanking the ULMs can regulate the marriage of phosphorylated SF1 with the U2AF⁶⁵ UHM (Wang et al. 2013; Zhang et al. 2013) or exacerbate the divorce of the phosphorylated ATX1 ULM from the U2AF⁶⁵ UHM in lieu of a 14-3-3 binding partner (Lim et al. 2008; de Chiara et al. 2009). Still questionable are the potential polygamous versus monogamous relationships of the multiple SF3b155 ULMs with different UHM-binding partners. Despite many exposés, whether new confessions of ULM extensions, phosphorylation-sensitivity, and cooperative binding will emerge as recurring dramas among UHM–ULM partners for now remain tantalizing family secrets. In the longer term, understanding the interplay among UHMs and ULMs may offer new therapeutic avenues for targeting the spliceosome (for review, see Bonnal et al. 2012), which has been highlighted recently for MYC-driven malignancies (Hirsch et al. 2015; Hsu et al. 2015; Koh et al. 2015) and already is promising for compounds that target the ULM-containing protein SF3b155 (for review, see Salton and Misteli 2016).

ACKNOWLEDGMENTS

This review was supported by National Institutes of Health grants GM070503 and GM117005 and an EvansMDS award to C.L.K.

REFERENCES

- Adam SA, Nakagawa T, Swanson MS, Woodruff TK, Dreyfuss G. 1986. mRNA polyadenylate-binding protein: gene isolation and sequencing and identification of a ribonucleoprotein consensus sequence. *Mol Cell Biol* 6: 2932–2943.
- Afroz T, Skrisovska L, Belloc E, Guillen-Boixet J, Mendez R, Allain FH. 2014. A fly trap mechanism provides sequence-specific RNA recognition by CPEB proteins. *Genes Dev* 28: 1498–1514.
- Avis JM, Allain FH, Howe PW, Varani G, Nagai K, Neuhaus D. 1996. Solution structure of the N-terminal RNP domain of U1A protein: the role of C-terminal residues in structure stability and RNA binding. *J Mol Biol* 257: 398–411.
- Bae E, Reiter NJ, Bingman CA, Kwan SS, Lee D, Phillips GN Jr, Butcher SE, Brow DA. 2007. Structure and interactions of the first three RNA recognition motifs of splicing factor prp24. *J Mol Biol* 367: 1447–1458.
- Bauer WJ, Heath J, Jenkins JL, Kielkopf CL. 2012. Three RNA recognition motifs participate in RNA recognition and structural organization by the pro-apoptotic factor TIA-1. *J Mol Biol* 415: 727–740.
- Blatter M, Dunin-Horkawicz S, Grishina I, Maris C, Thore S, Maier T, Bindereif A, Bujnicki JM, Allain FH. 2015. The signature of the five-

- stranded vRRM fold defined by functional, structural and computational analysis of the hnRNP L protein. *J Mol Biol* **427**: 3001–3022.
- Blom N, Sicheritz-Ponten T, Gupta R, Gammeltoft S, Brunak S. 2004. Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. *Proteomics* **4**: 1633–1649.
- Bonnal S, Vigevari L, Valcarcel J. 2012. The spliceosome as a target of novel antitumour drugs. *Nat Rev Drug Discov* **11**: 847–859.
- Bono F, Ebert J, Lorentzen E, Conti E. 2006. The crystal structure of the exon junction complex reveals how it maintains a stable grip on mRNA. *Cell* **126**: 713–725.
- Boudrez A, Beullens M, Waelkens E, Stalmans W, Bollen M. 2002. Phosphorylation-dependent interaction between the splicing factors SAP155 and NIPP1. *J Biol Chem* **277**: 31834–31841.
- Burley SK, Petsko GA. 1985. Aromatic-aromatic interaction: a mechanism of protein structure stabilization. *Science* **229**: 23–28.
- Cass DM, Berglund JA. 2006. The SF3b155 N-terminal domain is a scaffold important for splicing. *Biochemistry* **45**: 10092–10101.
- Chen HK, Fernandez-Funez P, Acevedo SF, Lam YC, Kaytor MD, Fernandez MH, Aitken A, Skoulakis EM, Orr HT, Botas J, et al. 2003. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. *Cell* **113**: 457–468.
- Corsini L, Bonnal S, Basquin J, Hothorn M, Scheffzek K, Valcarcel J, Sattler M. 2007. U2AF-homology motif interactions are required for alternative splicing regulation by SPF45. *Nat Struct Mol Biol* **14**: 620–629.
- Corsini L, Hothorn M, Stier G, Rybin V, Scheffzek K, Gibson TJ, Sattler M. 2009. Dimerization and protein binding specificity of the U2AF homology motif of the splicing factor Puf60. *J Biol Chem* **284**: 630–639.
- de Castro E, Sigrist CJ, Gattiker A, Bulliard V, Langendijk-Genevaux PS, Gasteiger E, Bairoch A, Hulo N. 2006. ScanProsite: detection of PROSITE signature matches and ProRule-associated functional and structural residues in proteins. *Nucleic Acids Res* **34**: W362–W365.
- de Chiara C, Menon RP, Strom M, Gibson TJ, Pastore A. 2009. Phosphorylation of S776 and 14-3-3 binding modulate ataxin-1 interaction with splicing factors. *PLoS One* **4**: e8372.
- Dinkel H, Chica C, Via A, Gould CM, Jensen LJ, Gibson TJ, Diella F. 2011. Phospho.ELM: a database of phosphorylation sites—update 2011. *Nucleic Acids Res* **39**: D261–D267.
- Dowhan DH, Hong EP, Auboeuf D, Dennis AP, Wilson MM, Berget SM, O'Malley BW. 2005. Steroid hormone receptor coactivation and alternative RNA splicing by U2AF⁶⁵-related proteins CAPER α and CAPER β . *Mol Cell* **17**: 429–439.
- Dreyfuss G, Swanson MS, Pinol-Roma S. 1988. Heterogeneous nuclear ribonucleoprotein particles and the pathway of mRNA formation. *Trends Biochem Sci* **13**: 86–91.
- Dutta J, Fan G, Gelinas C. 2008. CAPER α is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF- κ B oncoprotein v-Rel. *J Virol* **82**: 10792–10802.
- ElAntak L, Tzakos AG, Locker N, Lukavsky PJ. 2007. Structure of eIF3b RNA recognition motif and its interaction with eIF3j: structural insights into the recruitment of eIF3b to the 40 S ribosomal subunit. *J Biol Chem* **282**: 8165–8174.
- ElAntak L, Wagner S, Herrmannova A, Karaskova M, Rutkai E, Lukavsky PJ, Valasek L. 2010. The indispensable N-terminal half of eIF3j/HCR1 cooperates with its structurally conserved binding partner eIF3b/PRT1-RRM and with eIF1A in stringent AUG selection. *J Mol Biol* **396**: 1097–1116.
- Ferreon ACM, Ferreon JC, Wright PE, Deniz AA. 2013. Modulation of allostery by protein intrinsic disorder. *Nature* **498**: 390–394.
- Finn RD, Coghill P, Eberhardt RY, Eddy SR, Mistry J, Mitchell AL, Potter SC, Punta M, Qureshi M, Sangrador-Vegas A, et al. 2016. The Pfam protein families database: towards a more sustainable future. *Nucleic Acids Res* **44**: D279–D285.
- Fribourg S, Gatfield D, Izaurralde E, Conti E. 2003. A novel mode of RBD-protein recognition in the Y14-Mago complex. *Nat Struct Biol* **10**: 433–439.
- Galej WP, Wilkinson ME, Fica SM, Oubridge C, Newman AJ, Nagai K. 2016. Cryo-EM structure of the spliceosome immediately after branching. *Nature* **537**: 197–201.
- Gozani O, Potashkin J, Reed R. 1998. A potential role for U2AF-SAP 155 interactions in recruiting U2 snRNP to the branch site. *Mol Cell Biol* **18**: 4752–4760.
- Hastings ML, Allemand E, Duelli DM, Myers MP, Krainer AR. 2007. Control of pre-mRNA splicing by the general splicing factors PUF60 and U2AF⁶⁵. *PLoS One* **2**: e538.
- Hegele A, Kamburov A, Grossmann A, Sourlis C, Wowro S, Weimann M, Will CL, Pena V, Luhrmann R, Stelzl U. 2012. Dynamic protein–protein interaction wiring of the human spliceosome. *Mol Cell* **45**: 567–580.
- Hellemans J, Preobrazhenska O, Willaert A, Debeer P, Verdonck PC, Costa T, Janssens K, Menten B, Van Roy N, Vermeulen SJ, et al. 2004. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. *Nat Genet* **36**: 1213–1218.
- Hirsch CL, Coban Akdemir Z, Wang L, Jayakumaran G, Trcka D, Weiss A, Hernandez JJ, Pan Q, Han H, Xu X, et al. 2015. Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming. *Genes Dev* **29**: 803–816.
- Hsu TY, Simon LM, Neill NJ, Marcotte R, Sayad A, Bland CS, Echeverria GV, Sun T, Kurley SJ, Tyagi S, et al. 2015. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. *Nature* **525**: 384–388.
- Huang G, Zhou Z, Wang H, Kleinerman ES. 2012. CAPER- α alternative splicing regulates the expression of vascular endothelial growth VEGF₁₆₅ in Ewing's sarcoma cells. *Cancer* **118**: 2106–2116.
- Hudson BP, Martinez-Yamout MA, Dyson HJ, Wright PE. 2004. Recognition of the mRNA AU-rich element by the zinc finger domain of TIS11d. *Nat Struct Mol Biol* **11**: 257–264.
- Inoue D, Bradley RK, Abdel-Wahab O. 2016. Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. *Genes Dev* **30**: 989–1001.
- Joshi A, Coelho MB, Kotik-Kogan O, Simpson PJ, Matthews SJ, Smith CW, Curry S. 2011. Crystallographic analysis of polypyrimidine tract-binding protein-Raver1 interactions involved in regulation of alternative splicing. *Structure* **19**: 1816–1825.
- Jung DJ, Na SY, Na DS, Lee JW. 2002. Molecular cloning and characterization of CAPER, a novel coactivator of activating protein-1 and estrogen receptors. *J Biol Chem* **277**: 1229–1234.
- Kadlec J, Izaurralde E, Cusack S. 2004. The structural basis for the interaction between nonsense-mediated mRNA decay factors UPF2 and UPF3. *Nat Struct Mol Biol* **11**: 330–337.
- Kielkopf CL, Rodionova NA, Green MR, Burley SK. 2001. A novel peptide recognition mode revealed by the X-ray structure of a core U2AF³⁵/U2AF⁶⁵ heterodimer. *Cell* **106**: 595–605.
- Kielkopf CL, Lucke S, Green MR. 2004. U2AF homology motifs: protein recognition in the RRM world. *Genes Dev* **18**: 1513–1526.
- Koh CM, Bezzi M, Low DH, Ang WX, Teo SX, Gay FP, Al-Haddawi M, Tan SY, Osato M, Sabo A, et al. 2015. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. *Nature* **523**: 96–100.
- Konde E, Bourgeois B, Tellier-Lebegue C, Wu W, Perez J, Caputo S, Attanda W, Gasparini S, Charbonnier JB, Gilquin B, et al. 2010. Structural analysis of the Smad2-MAN1 interaction that regulates transforming growth factor- β signaling at the inner nuclear membrane. *Biochemistry* **49**: 8020–8032.
- Lahiri DK, Thomas JO. 1986. A cDNA clone of the hnRNP C proteins and its homology with the single-stranded DNA binding protein UP2. *Nucleic Acids Res* **14**: 4077–4094.
- Lallena MJ, Chalmers KJ, Llamazares S, Lamond AI, Valcarcel J. 2002. Splicing regulation at the second catalytic step by Sex-lethal involves 3' splice site recognition by SPF45. *Cell* **109**: 285–296.
- Lau CK, Diem MD, Dreyfuss G, Van Duyne GD. 2003. Structure of the Y14-Magoh core of the exon junction complex. *Curr Biol* **13**: 933–941.

- Lim J, Hao T, Shaw C, Patel AJ, Szabo G, Rual JF, Fisk CJ, Li N, Smolyar A, Hill DE, et al. 2006. A protein–protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. *Cell* **125**: 801–814.
- Lim J, Crespo-Barreto J, Jafar-Nejad P, Bowman AB, Richman R, Hill DE, Orr HT, Zoghbi HY. 2008. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. *Nature* **452**: 713–718.
- Lin F, Morrison JM, Wu W, Worman HJ. 2005. MAN1, an integral protein of the inner nuclear membrane, binds Smad2 and Smad3 and antagonizes transforming growth factor- β signaling. *Hum Mol Genet* **14**: 437–445.
- Liu J, He L, Collins I, Ge H, Libutti D, Li J, Egly JM, Levens D. 2000. The FBP interacting repressor targets TFIIF to inhibit activated transcription. *Mol Cell* **5**: 331–341.
- Liu J, Akoulitchev S, Weber A, Ge H, Chuikov S, Libutti D, Wang XW, Conaway JW, Harris CC, Conaway RC, et al. 2001. Defective interplay of activators and repressors with TFIIF in xeroderma pigmentosum. *Cell* **104**: 353–363.
- Loerch S, Kielkopf CL. 2015. Dividing and conquering the family of RNA recognition motifs: a representative case based on hnRNP L. *J Mol Biol* **427**: 2997–3000.
- Loerch S, Maucuer A, Manceau V, Green MR, Kielkopf CL. 2014. Cancer-relevant splicing factor CAPER α engages the essential splicing factor SF3b155 in a specific ternary complex. *J Biol Chem* **289**: 17325–17337.
- Madan V, Kanojia D, Li J, Okamoto R, Sato-Otsubo A, Kohlmann A, Sanada M, Grossmann V, Sundaresan J, Shiraishi Y, et al. 2015. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. *Nat Commun* **6**: 6042.
- Manceau V, Swenson M, Le Caer JP, Sobel A, Kielkopf CL, Maucuer A. 2006. Major phosphorylation of SF1 on adjacent Ser-Pro motifs enhances interaction with U2AF⁶⁵. *FEBS J* **273**: 577–587.
- Manceau V, Kielkopf CL, Sobel A, Maucuer A. 2008. Different requirements of the kinase and UHM domains of KIS for its nuclear localization and binding to splicing factors. *J Mol Biol* **381**: 748–762.
- Manceau V, Kremmer E, Nabel EG, Maucuer A. 2012. The protein kinase KIS impacts gene expression during development and fear conditioning in adult mice. *PLoS One* **7**: e43946.
- Maris C, Dominguez C, Allain FH. 2005. The RNA recognition motif, a plastic RNA-binding platform to regulate post-transcriptional gene expression. *FEBS J* **272**: 2118–2131.
- McLaughlin KJ, Jenkins JL, Kielkopf CL. 2011. Large favorable enthalpy changes drive specific RNA recognition by RNA recognition motif proteins. *Biochemistry* **50**: 1429–1431.
- Merendino L, Guth S, Bilbao D, Martinez C, Valcarcel J. 1999. Inhibition of *msl-2* splicing by Sex-lethal reveals interaction between U2AF³⁵ and the 3' splice site AG. *Nature* **402**: 838–841.
- Montemayor EJ, Curran EC, Liao HH, Andrews KL, Treba CN, Butcher SE, Brow DA. 2014. Core structure of the U6 small nuclear ribonucleoprotein at 1.7-Å resolution. *Nat Struct Mol Biol* **21**: 544–551.
- Naro C, Sette C. 2013. Phosphorylation-mediated regulation of alternative splicing in cancer. *Int J Cell Biol* **2013**: 151839.
- Nicodeme P. 2001. Fast approximate motif statistics. *J Comput Biol* **8**: 235–248.
- Okeyo-Owuor T, White BS, Chatrikhi R, Mohan DR, Kim S, Griffith M, Ding L, Ketkar-Kulkarni S, Hundal J, Laird KM, et al. 2015. U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing. *Leukemia* **29**: 909–917.
- Oubridge C, Ito N, Evans PR, Teo CH, Nagai K. 1994. Crystal structure at 1.92 Å resolution of the RNA-binding domain of the U1A spliceosomal protein complexed with an RNA hairpin. *Nature* **372**: 432–438.
- Page-McCaw PS, Amonlirdviman K, Sharp PA. 1999. PUF60: a novel U2AF⁶⁵-related splicing activity. *RNA* **5**: 1548–1560.
- Pan D, Estevez-Salmeron LD, Stroschein SL, Zhu X, He J, Zhou S, Luo K. 2005. The integral inner nuclear membrane protein MAN1 physically interacts with the R-Smad proteins to repress signaling by the transforming growth factor- β superfamily of cytokines. *J Biol Chem* **280**: 15992–16001.
- Price SR, Evans PR, Nagai K. 1998. Crystal structure of the spliceosomal U2B''-U2A' protein complex bound to a fragment of U2 small nuclear RNA. *Nature* **394**: 645–650.
- Rauhut R, Fabrizio P, Dybkov O, Hartmuth K, Pena V, Chari A, Kumar V, Lee CT, Urlaub H, Kastner B, et al. 2016. Molecular architecture of the *Saccharomyces cerevisiae* activated spliceosome. *Science* **353**: 1399–1405.
- Rideau AP, Gooding C, Simpson PJ, Monie TP, Lorenz M, Huttelmaier S, Singer RH, Matthews S, Curry S, Smith CW. 2006. A peptide motif in Raver1 mediates splicing repression by interaction with the PTB RRM2 domain. *Nat Struct Mol Biol* **13**: 839–848.
- Rudner DZ, Kanaar R, Breger KS, Rio DC. 1996. Mutations in the small subunit of the *Drosophila* U2AF splicing factor cause lethality and developmental defects. *Proc Natl Acad Sci* **93**: 10333–10337.
- Rupert PB, Xiao H, Ferre-D'Amare AR. 2003. U1A RNA-binding domain at 1.8 Å resolution. *Acta Crystallogr D Biol Crystallogr* **59**: 1521–1524.
- Sachs AB, Bond MW, Kornberg RD. 1986. A single gene from yeast for both nuclear and cytoplasmic polyadenylate-binding proteins: domain structure and expression. *Cell* **45**: 827–835.
- Salton M, Misteli T. 2016. Small molecule modulators of pre-mRNA splicing in cancer therapy. *Trends Mol Med* **22**: 28–37.
- Schellenberg MJ, Edwards RA, Ritchie DB, Kent OA, Golas MM, Stark H, Luhrmann R, Glover JN, MacMillan AM. 2006. Crystal structure of a core spliceosomal protein interface. *Proc Natl Acad Sci* **103**: 1266–1271.
- Seghezzi W, Chua K, Shanahan F, Gozani O, Reed R, Lees E. 1998. Cyclin E associates with components of the pre-mRNA splicing machinery in mammalian cells. *Mol Cell Biol* **18**: 4526–4536.
- Selenko P, Gregorovic G, Sprangers R, Stier G, Rhani Z, Kramer A, Sattler M. 2003. Structural basis for the molecular recognition between human splicing factors U2AF⁶⁵ and SF1/mBBP. *Mol Cell* **11**: 965–976.
- Shen H, Zheng X, Luecke S, Green MR. 2010. The U2AF35-related protein Urp contacts the 3' splice site to promote U12-type intron splicing and the second step of U2-type intron splicing. *Genes Dev* **24**: 2389–2394.
- Shi H, Xu RM. 2003. Crystal structure of the *Drosophila* Mago nashi-Y14 complex. *Genes Dev* **17**: 971–976.
- Shi Y, Reddy B, Manley JL. 2006. PP1/PP2A phosphatases are required for the second step of pre-mRNA splicing and target specific snRNP proteins. *Mol Cell* **23**: 819–829.
- Sickmier EA, Frato KE, Shen H, Paranawithana SR, Green MR, Kielkopf CL. 2006. Structural basis for polypyrimidine tract recognition by the essential pre-mRNA splicing factor U2AF⁶⁵. *Mol Cell* **23**: 49–59.
- Soares LM, Zanier K, Mackereth C, Sattler M, Valcarcel J. 2006. Intron removal requires proofreading of U2AF/3' splice site recognition by DEK. *Science* **312**: 1961–1965.
- Spadaccini R, Reidt U, Dybkov O, Will C, Frank R, Stier G, Corsini L, Wahl MC, Luhrmann R, Sattler M. 2006. Biochemical and NMR analyses of an SF3b155-p14-U2AF-RNA interaction network involved in branch point definition during pre-mRNA splicing. *RNA* **12**: 410–425.
- Stepanyuk GA, Serrano P, Peralta E, Farr CL, Axelrod HL, Geralt M, Das D, Chiu HJ, Jaroszewski L, Deacon AM, et al. 2016. UHM-ULM interactions in the RBM39-U2AF65 splicing-factor complex. *Acta Crystallogr D Struct Biol* **72**: 497–511.
- Teplava M, Patel DJ. 2008. Structural insights into RNA recognition by the alternative-splicing regulator muscleblind-like MBNL1. *Nat Struct Mol Biol* **15**: 1343–1351.
- Thickman KR, Swenson MC, Kabogo JM, Gryczynski Z, Kielkopf CL. 2006. Multiple U2AF⁶⁵ binding sites within SF3b155: thermodynamic and spectroscopic characterization of protein–protein interactions among pre-mRNA splicing factors. *J Mol Biol* **356**: 664–683.
- Tripsianes K, Friberg A, Barrandon C, Brooks M, van Tilbeurgh H, Seraphin B, Sattler M. 2014. A novel protein-protein interaction in

- the RES (REtention and Splicing) complex. *J Biol Chem* **289**: 28640–28650.
- Tunnicliffe RB, Hautbergue GM, Kalra P, Jackson BR, Whitehouse A, Wilson SA, Golovanov AP. 2011. Structural basis for the recognition of cellular mRNA export factor REF by herpes viral proteins HSV-1 ICP27 and HVS ORF57. *PLoS Pathog* **7**: e1001244.
- Tunnicliffe RB, Hautbergue GM, Wilson SA, Kalra P, Golovanov AP. 2014. Competitive and cooperative interactions mediate RNA transfer from herpesvirus saimiri ORF57 to the mammalian export adaptor ALYREF. *PLoS Pathog* **10**: e1003907.
- Wan R, Yan C, Bai R, Huang G, Shi Y. 2016a. Structure of a yeast catalytic step I spliceosome at 3.4 Å resolution. *Science* **353**: 895–904.
- Wan R, Yan C, Bai R, Wang L, Huang M, Wong CC, Shi Y. 2016b. The 3.8 Å structure of the U4/U6.U5 tri-snRNP: insights into spliceosome assembly and catalysis. *Science* **351**: 466–475.
- Wang C, Chua K, Seghezzi W, Lees E, Gozani O, Reed R. 1998. Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. *Genes Dev* **12**: 1409–1414.
- Wang X, Bruderer S, Rafi Z, Xue J, Milburn PJ, Kramer A, Robinson PJ. 1999. Phosphorylation of splicing factor SF1 on Ser20 by cGMP-dependent protein kinase regulates spliceosome assembly. *EMBO J* **18**: 4549–4559.
- Wang W, Maucuer A, Gupta A, Manceau V, Thickman KR, Bauer WJ, Kennedy SD, Wedekind JE, Green MR, Kielkopf CL. 2013. Structure of phosphorylated SF1 bound to U2AF⁶⁵ in an essential splicing factor complex. *Structure* **21**: 197–208.
- Weber C, Schreiber TB, Daub H. 2012. Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. *J Proteomics* **75**: 1343–1356.
- Will CL, Schneider C, MacMillan AM, Katopodis NF, Neubauer G, Wilm M, Luhrmann R, Query CC. 2001. A novel U2 and U11/U12 snRNP protein that associates with the pre-mRNA branch site. *EMBO J* **20**: 4536–4546.
- Wright PE, Dyson HJ. 2015. Intrinsically disordered proteins in cellular signalling and regulation. *Nat Rev Mol Cell Biol* **16**: 18–29.
- Wu S, Romfo CM, Nilsen TW, Green MR. 1999. Functional recognition of the 3' splice site AG by the splicing factor U2AF³⁵. *Nature* **402**: 832–835.
- Wulf G, Finn G, Suizu F, Lu KP. 2005. Phosphorylation-specific prolyl isomerization: is there an underlying theme? *Nat Cell Biol* **7**: 435–441.
- Wysoczanski P, Schneider C, Xiang S, Munari F, Trowitzsch S, Wahl MC, Luhrmann R, Becker S, Zweckstetter M. 2014. Cooperative structure of the heterotrimeric pre-mRNA retention and splicing complex. *Nat Struct Mol Biol* **21**: 911–918.
- Yan C, Hang J, Wan R, Huang M, Wong CC, Shi Y. 2015. Structure of a yeast spliceosome at 3.6-angstrom resolution. *Science* **349**: 1182–1191.
- Yan C, Wan R, Bai R, Huang G, Shi Y. 2016. Structure of a yeast activated spliceosome at 3.5 Å resolution. *Science* **353**: 904–911.
- Yoshida H, Park SY, Oda T, Akiyoshi T, Sato M, Shirouzu M, Tsuda K, Kuwasako K, Unzai S, Muto Y, et al. 2015. A novel 3' splice site recognition by the two zinc fingers in the U2AF small subunit. *Genes Dev* **29**: 1649–1660.
- Zamore PD, Patton JG, Green MR. 1992. Cloning and domain structure of the mammalian splicing factor U2AF. *Nature* **355**: 609–614.
- Zhang M, Zamore PD, Carmo-Fonseca M, Lamond AI, Green MR. 1992. Cloning and intracellular localization of the U2 small nuclear ribonucleoprotein auxiliary factor small subunit. *Proc Natl Acad Sci* **89**: 8769–8773.
- Zhang Y, Madl T, Bagdiul I, Kern T, Kang HS, Zou P, Mausbacher N, Sieber SA, Kramer A, Sattler M. 2013. Structure, phosphorylation and U2AF⁶⁵ binding of the N-terminal domain of splicing factor 1 during 3'-splice site recognition. *Nucleic Acids Res* **41**: 1343–1354.
- Zhou Z, Fu XD. 2013. Regulation of splicing by SR proteins and SR protein-specific kinases. *Chromosoma* **122**: 191–207.
- Zorio DA, Blumenthal T. 1999. Both subunits of U2AF recognize the 3' splice site in *Caenorhabditis elegans*. *Nature* **402**: 835–838.

RNA

A PUBLICATION OF THE RNA SOCIETY

Unmasking the U2AF homology motif family: a bona fide protein–protein interaction motif in disguise

Sarah Loerch and Clara L. Kielkopf

RNA 2016 22: 1795-1807

References

This article cites 108 articles, 33 of which can be accessed free at:
<http://rnajournal.cshlp.org/content/22/12/1795.full.html#ref-list-1>

Creative Commons License

This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see <http://rnajournal.cshlp.org/site/misc/terms.xhtml>). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *RNA* go to:
<http://rnajournal.cshlp.org/subscriptions>